CompletedEUCTR 2012-004334-42
A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients with Bipolarity type I
This historical record does not confirm current site availability.
Historical research recordHungary
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who was this study for?
This study was for people with type I bipolarity. Other eligibility criteria applied.
- Listed locations
- Hungary
- Study phase
- Phase 3 / Phase 4This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 1,000
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3, Phase 4This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- Hungary
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2012-004334-42
- Official title
Show the full official title
A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients with Bipolar I Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Hungary
Registry details
Historical country statuses
- Hungary — Completed
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Who was this study for?
This study was for people with type I bipolarity. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Adjunctive Aripiprazole Therapy in the Treatment of Mania in Bipolarity type I Pat...
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/day) as Adjunctive Therapy in Adults With Major Depressio...